A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

计划入组 4,050 人 · 首次发布于 2026 年 3 月 27 日

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

计划入组 48 人 · 首次发布于 2008 年 9 月 19 日

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

计划入组 720 人 · 首次发布于 2025 年 4 月 2 日

mRNA vaccine (intramuscular/ pandemic influenza H5 virus infection)

pandemic influenza H1 and H5 vaccine

pandemic influenza vaccine

Research Institute of Influenza

Russia

Sernova Corp

Canada

CEL-SCI

United States

Moderna Secures $54.3 Million CEPI Funding for First mRNA Bird Flu Vaccine Pivotal Trial

Moderna Secures $590M HHS Award to Advance mRNA-Based Pandemic Flu Vaccines

Intranasal H5N1 Vaccine Shows Broad Immune Response in Phase I Trial